Issues Facing TB Control (8) the Future of BCG/VACCINE Development

D. Lowrie

DOI: https://doi.org/10.1177/00369330000450S126

2000-10-01

Scottish Medical Journal

Abstract:Introduction There is a new generation ofnovel candidate vaccines against tuberculosis under development. But the hurdles (clinical, political and economic) that must be overcome before there can be a proper clinical appraisal of any one of them are daunting. The tasks that we require new vaccines to successfully accomplish immunologically are neither simple nor yet understood. They can be simply stated: we want vaccines to protect against future new infection (prevention) and to treat existing disease (therapy) so that there is less pathology, fewer relapses and fewer anti-mycobacterial drugs are needed. Less obviously, we would also like a vaccine to eliminate the dormant persistent M tuberculosis infection that produces most of the active disease currently seen in formerly high prevalence countries such as those of the West. However, for both prevention and therapy we need vaccines to selectively promote beneficial and not harmful kinds of immune response and our knowledge ofhow to do this, in anything other than an empirical fashion, is still only partial. The huge differences in protective efficacy of BCG against adult pulmonary tuberculosis in different parts ofthe world still await proper explanation. Vaccination of adolescents gives protection that ranges from high (eg. almost 80% in the UK) to zero (eg. in South India). The protective effect in the UK becomes undetectable 15 years later. It is generally believed that environmental mycobacteria interfere with the efficacy of BCG, both in man and in cattle. BCG vaccination at birth, before sensitisation to other mycobacteria, confers substantial protection against the essentially non-infectious childhood forms of tuberculosis. However, it is not clear that protection following vaccination at birth extends to the infectious pulmonary form seen in adults. Neither is it clear if sensitisation by the environment can confer full protection against pulmonary tuberculosis (equal to the maximum effect ofBCG). This would leave no room for BCG to add anything. Alternatively, the immune system may become subverted so that protective responses can no longer be evoked by BeG. The distinction is important because it could profoundly affect the whole approach to finding something better than BCG.